Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.42 |
| ▸ | WNT3A | P56704 | 3/20 | 0.42 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078561 | 0.81 | KMT2A (0.49) | KMT2AL3MBTL1LMNANAPRTALDH1A1 | |
| SCHEMBL10861570 | 0.80 | KMT2A (0.51) | KMT2ACES2CES1L3MBTL1LMNA | |
| SCHEMBL4959969 | 0.79 | LMNA (0.59) | KMT2ACES2CES1L3MBTL1LMNA | |
| SCHEMBL8764829 | 0.79 | CTNNB1 (0.44) | KMT2AL3MBTL1ALDH1A1RAB9AKDM4E | |
| SCHEMBL8833877 | 0.77 | KDM4E (0.59) | KMT2AL3MBTL1LMNANAPRTALDH1A1 | |
| SCHEMBL2745986 | 0.77 | KMT2A (0.47) | KMT2AL3MBTL1LMNANAPRTALDH1A1 | |
| SCHEMBL16211860 | 0.76 | NAPRT (0.59) | KMT2ACES2CES1L3MBTL1LMNA | |
| SCHEMBL12143400 | 0.76 | KMT2A (0.55) | KMT2ACES2CES1L3MBTL1LMNA | |
| SCHEMBL87791 | 0.75 | KMT2A (0.75) | KMT2ACES2CES1L3MBTL1LMNA | |
| SCHEMBL31369148 | 0.75 | KMT2A (0.75) | KMT2ACES2CES1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9597327-B2 | Synthesis of (R)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150290187-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | Progenics Pharmaceuticals., Inc. | 2015-10-15 | — | — | US | disclosed |
| US-8343992-B2 | Synthesis of R-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100311781-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. | 2010-12-09 | — | — | US | disclosed |
| US-6440933-B1 | PEPTIDE DERIVATIVES WHICH ARE DIHYDROPYRIDINE-PYRIDINIUM SALT-TYPE REDOX TARGETOR MOIETY, A BULKY LIPOPHILIC FUNCTION AND AN AMINO ACID/DIPEPTIDE/TRIPEPTIDE SPACER; GROWTH FACTOR INHIBITOR, ESPECIALLY SOMATOSTATIN ANALOGS, RETINA | UNIVERSITY OF FLORIDA | 2002-08-27 | — | — | US | disclosed |
| US-6214316-B1 | COMPRISING CYCLIC PEPTIDE DERIVATIVES; KIT FOR PREPARING A RADIOPHARMACEUTICAL PREPARATION, COMPRISING A SEALED VIAL CONTAINING A PREDETERMINED QUANTITY OF THE PEPTIDE | DIATIDE, INC. | 2001-04-10 | — | — | US | disclosed |
| US-6022857-A | Radiolabeled compounds for thrombus imaging | DIATIDE, INC. (US) | 2000-02-08 | — | — | US | disclosed |
| US-5849260-A | Technetium-99M labeled peptides for thrombus imaging | DIATIDE, INC. (US) | 1998-12-15 | — | — | US | disclosed |
| US-5776428-A | Technetium-99m labeled peptides for imaging | DIATIDE, INC. (US) | 1998-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311781-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | OPRM1, OPRK1, OPRL1 | KMT2A 411/4885CES2 1437/4885CES1 2203/4885 |
| US-20150290187-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | OPRM1, OPRL1, OPRK1 | KMT2A 526/4885CES2 1194/4885CES1 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.